Protagenic Therapeutics, Inc.
PTIX- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001022899
In the last 90 days, Protagenic Therapeutics, Inc. insiders filed 7 open-market purchases and 0 sales; 2 institutions reported holding it in 13F filings for Q2 2026, worth $25.4K in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Protagenic Therapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 11 | 12 | +1 |
| Shares | 100.4K | 116.5K | +16.1K (+16.0%) |
| Value | $344.4K | $150.9K | −$193.5K (−56.2%) |
New holders (4)
Institutions that held Protagenic Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 23,311 | $30.3K | 0.00% |
| Geode Capital Management, LLC | 12,182 | $15.8K | 0.00% |
| Raymond James Financial Inc | 10,001 | $13.0K | 0.00% |
| Advisor Group Holdings, Inc. | 49 | $64 | 0.00% |
Sold out (3)
Institutions that held Protagenic Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Connective Capital Management, LLC | 28,600 | $98.1K |
| Citigroup Inc | 1,776 | $6.09K |
| UBS Group AG | 56 | $192 |